{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:12:37Z","timestamp":1776183157937,"version":"3.50.1"},"reference-count":28,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>The present study is to investigate the association between T790M status and clinical\ncharacteristics of patients with EGFR-sensitive advanced non-small cell lung cancer (NSCLC)\nwho progressed the initial epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKIs)\nadministration.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A total of 167 patients with EGFR-sensitive mutations advanced NSCLC who had successful\ngenetic tests and progressed the initial EGFR-TKI treatment were included in this study retrospectively.\nThe clinical and demographic characteristics of these patients were collected, which\nwere manifested as pathological type, metastasis location, initial biopsy method, initial genetic test\nspecimens, and baseline gene mutations status. Correlation analysis between T790M status and\nthese characteristics was performed and prognostic analysis regarding the different subgroups was\ncarried out accordingly.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The prevalence of secondary T790M after resistance to initial EGFR-TKIs among the 167\npatients was 52.7%. Correlation analysis indicated that the median progression-free Survival (PFS)\nto initial EGFR-TKIs &gt;12 months were more likely to develop secondary T790M in univariate\nanalysis. However, the conclusion failed to show statistically significant in multivariate analysis.\nAdditionally, patients with intracranial progression of initial EGFR-TKIs therapy were associated\nwith secondary EGFR-T790M. However, it should be noted that those whose best overall response\nwas partial response (PR) during the EGFR-TKI therapy were relevant to secondary T790M.\nFurthermore, The median PFS of the initial EGFR-TKIs administration was longer among patients\nwith T790M positive mutation and patients with PR reaction than those without T790M mutation\nand patients with stable disease (SD), respectively (median PFS: 13.6 vs. 10.9 months, P=0.023)\nand (median PFS: 14.0 vs. 10.1 months, P=0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This retrospective study highlighted the real-world evidence that the best efficacy and\nintracranial progression with initial EGFR-TKIs therapy among patients with advanced NSCLC\nmight be the promising indicators to predict the occurrence of EGFR-T790M. Patients with PR\nreaction and T790M positive mutation conferred longer PFS of the initial EGFR-TKIs administration.\nAlso, the conclusion should be confirmed in more patients with advanced NSCLC subsequently.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1386207326666230606100729","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T07:37:37Z","timestamp":1686123457000},"page":"845-853","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Correlation Analysis between T790M Status and Clinical Characteristics\nof Patients with EGFR-sensitive Mutation Advanced NSCLC who\nProgressed after the First Generation and First-line EGFR-TKIs\nAdministration: A Real-world Exploratory Study"],"prefix":"10.2174","volume":"27","author":[{"given":"Ye","family":"Zhen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xingtai Medical College, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Bo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xingtai Medical College, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Ying","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Quyang Cancer Hospital\/ Hengzhou Hospital, Baoding, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Ting","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Guo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Ju","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The First Affiliated Hospital of Xingtai Medical College, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ning","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the First Hospital of Xingtai, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xingtai Medical College, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CCO.0000000000000703","volume":"33","author":"Wu F.","year":"2021","unstructured":"Wu F.; Wang L.; Zhou C.; Lung cancer in China: current and prospect. Curr Opin Oncol  2021,33(1),40-46","journal-title":"Curr Opin Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3322\/caac.20102","volume":"61","author":"Ramalingam S.S.","year":"2011","unstructured":"Ramalingam S.S.; Owonikoko T.K.; Khuri F.R.; Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin  2011,61(2),91-112","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2147\/IJGM.S279023","volume":"13","author":"Zhang J.","year":"2020","unstructured":"Zhang J.; Mao W.; Chen Z.; Gu H.; Lian C.; Clinical significance of Has_circ_0060937 in bone metastasis of NSCLC. Int J Gen Med  2020,13,1115-1121","journal-title":"Int J Gen Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"Paz-Ares L.","year":"2017","unstructured":"Paz-Ares L.; Tan E.H.; O\u2019Byrne K.; Zhang L.; Hirsh V.; Boyer M.; Yang J.C.H.; Mok T.; Lee K.H.; Lu S.; Shi Y.; Lee D.H.; Laskin J.; Kim D.W.; Laurie S.A.; K\u00f6lbeck K.; Fan J.; Dodd N.; M\u00e4rten A.; Park K.; Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol  2017,28(2),270-277","journal-title":"Ann Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"Maemondo M.","year":"2010","unstructured":"Maemondo M.; Inoue A.; Kobayashi K.; Sugawara S.; Oizumi S.; Isobe H.; Gemma A.; Harada M.; Yoshizawa H.; Kinoshita I.; Fujita Y.; Okinaga S.; Hirano H.; Yoshimori K.; Harada T.; Ogura T.; Ando M.; Miyazawa H.; Tanaka T.; Saijo Y.; Hagiwara K.; Morita S.; Nukiwa T.; Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med  2010,362(25),2380-2388","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"Saito H.","year":"2019","unstructured":"Saito H.; Fukuhara T.; Furuya N.; Watanabe K.; Sugawara S.; Iwasawa S.; Tsunezuka Y.; Yamaguchi O.; Okada M.; Yoshimori K.; Nakachi I.; Gemma A.; Azuma K.; Kurimoto F.; Tsubata Y.; Fujita Y.; Nagashima H.; Asai G.; Watanabe S.; Miyazaki M.; Hagiwara K.; Nukiwa T.; Morita S.; Kobayashi K.; Maemondo M.; Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol  2019,20(5),625-635","journal-title":"Lancet Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12931-019-1137-4","volume":"20","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Zeng Y.; Liu T.; Du W.; Zhu J.; Liu Z.; Huang J.; The canonical TGF-\u03b2\/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer. Respir Res  2019,20(1),164","journal-title":"Respir Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","volume":"17","author":"Oxnard G.R.","year":"2011","unstructured":"Oxnard G.R.; Arcila M.E.; Sima C.S.; Riely G.J.; Chmielecki J.; Kris M.G.; Pao W.; Ladanyi M.; Miller V.A.; Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res  2011,17(6),1616-1622","journal-title":"Clin Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"99429","DOI":"10.18632\/oncotarget.19681","volume":"8","author":"Ma G.","year":"2017","unstructured":"Ma G.; Zhang J.; Jiang H.; Zhang N.; Yin L.; Li W.; Zhou Q.; Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors. Oncotarget  2017,8(59),99429-99437","journal-title":"Oncotarget"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/ijc.IJC_540_17","volume":"54","author":"Chougule A.","year":"2017","unstructured":"Chougule A.; Basak S.; Epidermal growth factor receptor T790M testing in progressed lung cancer: A review of sensitive methods for analysis of tissue and liquid biopsy samples. Indian J Cancer  2017,54(5)(Suppl.),45","journal-title":"Indian J Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11523-014-0312-2","volume":"9","author":"Li Z.","year":"2014","unstructured":"Li Z.; Zhang Y.; Bao W.; Jiang C.; Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis. Target Oncol  2014,9(4),381-388","journal-title":"Target Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40880-018-0303-2","volume":"38","author":"Zhang S.","year":"2018","unstructured":"Zhang S.; Zhu L.; Xia B.; Chen E.; Zhao Q.; Zhang X.; Chen X.; Chen X.; Ma S.; Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observat. Cancer Commun (Lond)  2018,38(1),28","journal-title":"Cancer Commun (Lond)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"Sequist L.V.","year":"2011","unstructured":"Sequist L.V.; Waltman B.A.; Dias-Santagata D.; Digumarthy S.; Turke A.B.; Fidias P.; Bergethon K.; Shaw A.T.; Gettinger S.; Cosper A.K.; Akhavanfard S.; Heist R.S.; Temel J.; Christensen J.G.; Wain J.C.; Lynch T.J.; Vernovsky K.; Mark E.J.; Lanuti M.; Iafrate A.J.; Mino-Kenudson M.; Engelman J.A.; Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med  2011,3(75),75ra26","journal-title":"Sci Transl Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","volume":"10","author":"Hata A.","year":"2015","unstructured":"Hata A.; Katakami N.; Yoshioka H.; Kaji R.; Masago K.; Fujita S.; Imai Y.; Nishiyama A.; Ishida T.; Nishimura Y.; Yatabe Y.; Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non\u2013Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI. J Thorac Oncol  2015,10(11),1553-1559","journal-title":"J Thorac Oncol"},{"key":"ref=15","first-page":"1025","volume":"35","author":"Hata A.","year":"2015","unstructured":"Hata A.; Katakami N.; Yoshioka H.; Takeshita J.; Tanaka K.; Masago K.; Fujita S.; Kaji R.; Imai Y.; Monden K.; Matsumoto T.; Nagata K.; Otsuka K.; Tachikawa R.; Tomii K.; Kunimasa K.; Iwasaku M.; Nishiyama A.; Ishida T.; Nishimura Y.; Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Anticancer Res  [doi].2015,35(2),1025-1031","journal-title":"Anticancer Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1186\/s12885-018-5153-4","volume":"18","author":"Yoshimura A.","year":"2018","unstructured":"Yoshimura A.; Yamada T.; Okura N.; Takeda T.; Furutani W.; Kubota Y.; Shiotsu S.; Hiranuma O.; Nishioka N.; Chihara Y.; Tamiya N.; Kaneko Y.; Uchino J.; Takayama K.; The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. BMC Cancer  2018,18(1),1241","journal-title":"BMC Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.cllc.2017.05.004","volume":"18","author":"Oya Y.","year":"2017","unstructured":"Oya Y.; Yoshida T.; Kuroda H.; Shimizu J.; Horio Y.; Sakao Y.; Inaba Y.; Hida T.; Yatabe Y.; Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clin Lung Cancer  2017,18(6),698-705.e2","journal-title":"Clin Lung Cancer"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"36458","DOI":"10.1038\/srep36458","volume":"6","author":"Matsuo N.","year":"2016","unstructured":"Matsuo N.; Azuma K.; Sakai K.; Hattori S.; Kawahara A.; Ishii H.; Tokito T.; Kinoshita T.; Yamada K.; Nishio K.; Hoshino, T Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of t790m Mutation in EGFR-mutant lung cancer patients. Sci Rep  2016,6,36458","journal-title":"Sci Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.cllc.2017.06.004","volume":"19","author":"Gaut D.","year":"2018","unstructured":"Gaut D.; Sim M.S.; Yue Y.; Wolf B.R.; Abarca P.A.; Carroll J.M.; Goldman J.W.; Garon E.B.; Clinical implications of the T790M mutation in disease characteristics and treatment response in patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Non\u2013Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer  2018,19(1),e19-e28","journal-title":"Clin Lung Cancer"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2017.07.002","volume":"19","author":"Kawamura T.","year":"2018","unstructured":"Kawamura T.; Kenmotsu H.; Omori S.; Nakashima K.; Wakuda K.; Ono A.; Naito T.; Murakami H.; Omae K.; Mori K.; Tanigawara Y.; Nakajima T.; Ohde Y.; Endo M.; Takahashi T.; Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non\u2013small-cell lung cancer. Clin Lung Cancer  2018,19(2),e247-e252","journal-title":"Clin Lung Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","volume":"3","author":"Chmielecki J.","year":"2011","unstructured":"Chmielecki J.; Foo J.; Oxnard G.R.; Hutchinson K.; Ohashi K.; Somwar R.; Wang L.; Amato K.R.; Arcila M.; Sos M.L.; Socci N.D.; Viale A.; de Stanchina E.; Ginsberg M.S.; Thomas R.K.; Kris M.G.; Inoue A.; Ladanyi M.; Miller V.A.; Michor F.; Pao W.; Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med  2011,3(90),90ra59","journal-title":"Sci Transl Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"20466","DOI":"10.18632\/oncotarget.4058","volume":"6","author":"Iwama E.","year":"2015","unstructured":"Iwama E.; Takayama K.; Harada T.; Okamoto I.; Ookubo F.; Kishimoto J.; Baba E.; Oda Y.; Nakanishi Y.; Highly sensitive and quantitative evaluation of the EGFR T790M mutation by nanofluidic digital PCR. Oncotarget  2015,6(24),20466-20473","journal-title":"Oncotarget"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"20913","DOI":"10.1038\/srep20913","volume":"6","author":"Zheng D.","year":"2016","unstructured":"Zheng D.; Ye X.; Zhang M.Z.; Sun Y.; Wang J.Y.; Ni J.; Zhang H.P.; Zhang L.; Luo J.; Zhang J.; Tang L.; Su B.; Chen Z.; Zhu G.; Gu Y.; Xu J.F.; Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep  2016,6,20913","journal-title":"Sci Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2014.03.016","volume":"85","author":"Kuiper J.L.","year":"2014","unstructured":"Kuiper J.L.; Heideman D.A.M.; Thunnissen E.; Paul M.A.; van Wijk A.W.; Postmus P.E.; Smit E.F.; Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer  2014,85(1),19-24","journal-title":"Lung Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1097\/JTO.0b013e3182a407fa","volume":"8","author":"Norkowski E.","year":"2013","unstructured":"Norkowski E.; Ghigna M.R.; Lacroix L.; Le Chevalier T.; Fadel \u00c9.; Dartevelle P.; Dorfmuller P.; Thomas de Montpr\u00e9ville V.; Small-cell carcinoma in the setting of pulmonary adenocarcinoma: New insights in the era of molecular pathology. J Thorac Oncol  2013,8(10),1265-1271","journal-title":"J Thorac Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/annonc\/mdv495","volume":"27","author":"Haratani K.","year":"2016","unstructured":"Haratani K.; Hayashi H.; Watanabe S.; Kaneda H.; Yoshida T.; Takeda M.; Shimizu T.; Nakagawa K.; Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: Successful treatment of one case with rociletinib. Ann Oncol  2016,27(1),200-202","journal-title":"Ann Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3892\/mco.2019.1880","volume":"11","author":"Yamaguchi F.","year":"2019","unstructured":"Yamaguchi F.; Kato E.; Wakabayashi A.; Shikama Y.; Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review. Mol Clin Oncol  2019,11(2),127-131","journal-title":"Mol Clin Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.lungcan.2019.01.012","volume":"130","author":"Lee K.","year":"2019","unstructured":"Lee K.; Kim Y.; Jung H.A.; Lee S.H.; Ahn J.S.; Ahn M.J.; Park K.; Choi Y.L.; Sun J.M.; Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. Lung Cancer  2019,130,87-92","journal-title":"Lung Cancer"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207326666230606100729","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217674\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1386207326666230606100729","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T06:13:52Z","timestamp":1714630432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217674\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1386207326666230606100729","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}